Kailera Therapeutics (KLRA) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tyra Biosciences is the larger company by market cap ($1.37 billion vs $1.30 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRA | TYRA |
|---|---|---|
| Share price | $10.00 | $19.97 |
| Market cap | $1.30B | $1.37B |
| 1-day change | -5.03% | -2.06% |
| YTD return | — | -24.04% |
| 1-year return | — | +46.52% |
| 5-year return | — | +22.22% |
| EPS (TTM) | $-4.51 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.23 | $40.65 |
| 52-week low | $9.76 | $13.29 |
| Distance from 52-week high | -64.58% | -50.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +324.00% | +137.61% |
| Average volume | 861.01K | 857.13K |
| Shares outstanding | 129.64M | 68.76M |
| Employees | 145 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
KLRA vs TYRA FAQ
Which is bigger, Kailera Therapeutics or Tyra Biosciences?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.37B compared with $1.30B for Kailera Therapeutics (KLRA).
Are Kailera Therapeutics and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.